α-Methyl-α-(4-chlorphenoxy)-valeriansaeure | 91767-69-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: α-Methyl-α-(4-chlorphenoxy)-valeriansaeure
• 英文别名: Ethyl p-chlorophenoxy isobutyric acid；2-(4-chlorophenoxy)-2-methylpentanoic acid
• CAS: 91767-69-0
• 化学式: C₁₂H₁₅ClO₃
• 分子量: 242.702
• InChiKey: NAJMFEZOIWEPPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  氯仿 、 2-戊酮 、 对氯苯酚 在 sodium hydroxide 作用下， 生成 α-Methyl-α-(4-chlorphenoxy)-valeriansaeure
  参考文献：
  名称：

  MELANDRI; BUTTINI; GALIMBERTI, Bollettino Chimico Farmaceutico, 1963, vol. 102, p. 777 - 783

  摘要：

  DOI：

文献信息

• Medicament for curing arteriosclerosis, comprising pyrimido (2,1-b) benzothiazole derivative
  申请人：MECT CORPORATION

  公开号：EP0261439A2

  公开（公告）日：1988-03-30

  A medicament for curing arteriosclerosis which comprises pyrimido [2,1-b] benzothiazole derivative.

  一种治疗动脉硬化的药物，由嘧啶并[2,1-b]苯并噻唑衍生物组成。
• CARDIOVASCULAR AND BONE TREATMENT USING ISOFLAVONES
  申请人：Novogen Research Pty. Ltd.

  公开号：EP1173165A1

  公开（公告）日：2002-01-23
• EP1173165A4
  申请人：——

  公开号：EP1173165A4

  公开（公告）日：2004-05-12
• Cardiovascular and bone treatment using isoflavones
  申请人：Novogen Research Pty Ltd.

  公开号：US20040072765A1

  公开（公告）日：2004-04-15

  Compositions comprising formononetin and/or one or more isoflavones selected from biochanin, genistein and daidzein, in a therapeutically effective ratio of formononetin to said isoflavones of 15:1 to 2:1, optionally in association with one or more carriers, excipients, auxiliaries and/or diluents are described. Also described are methods of treatment involving such compositions including the prevention and/or treatment of cardiovascular disease, the beneficial alteration of blood lipoprotein levels, or a reduction in the risk of vascular disease, or a reduction in the risk of coronary heart disease, or a reduction in the risk of arteriosclerosis, or in the beneficial alteration or maintenance of bone density such as in the prevention or treatment of osteoporosis, and/or in the prevention and/or treatment of bone fracture.
• Compositions and Methods for Treating or Preventing Glaucoma or Progression Thereof
  申请人：Bartels Stephen P.

  公开号：US20080058373A1

  公开（公告）日：2008-03-06

  A composition for treating or preventing glaucoma or its progression comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It may be used in combination with another therapy directed to reducing intraocular pressure.